Cemacabtagene ansegedleucel

Highest phase reached

Phase 2

Drug type

Gene

allogeneic t lymphocytes obtained from peripheral blood mononuclear cells by leukapheresis of healthy volunteer donors transduced with a self inactivating non replicating lentiviral vector encoding a chimeric antigen receptor car targeting human cd19 the cells are also genetically modified using transcription activator like tal effector nucleases that are transiently delivered into the cell as mrnas via electroporation and code for two pairs one pair is designed for disruption of the t cell receptor alpha constant trac and the other for disruption of the cd52 locus
Allogeneic T lymphocytes obtained from peripheral blood mononuclear cells by leukapheresis of healthy volunteer donors, transduced with a self-inactivating, non-replicating lentiviral vector encoding a chimeric antigen receptor (CAR) targeting human CD19. The cells are also genetically modified using transcription activator-like (TAL) effector nucleases that are transiently delivered into the cell as mRNAs via electroporation and code for two pairs: one pair is designed for disruption of the T-cell receptor alpha constant (TRAC) and the other for disruption of the CD52 locus
cemacabtagen ansegedleucel
Cemacabtagen ansegedleucel
cemacabtagene ansegedleucel
Cemacabtagene ansegedleucel
cemacabtagene ansegedleucel [INN]
Cemacabtagene ansegedleucel [WHO-DD]
cemacabtagene ansegedleucel inn
cemacabtagene ansegedleucel who dd

FDA ingredient codes (UNII)

Related records